Definium Therapeutics (DFTX) Stock Analysis

What Definium Therapeutics does

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Key metrics

ETFs linked to DFTX

Broad-market and Healthcare sector ETFs an investor holding Definium Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how DFTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Definium Therapeutics?

Definium Therapeutics trades under the ticker DFTX on NASDAQ.

Which exchange is DFTX listed on?

DFTX is listed on NASDAQ.

What sector does Definium Therapeutics operate in?

Definium Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze DFTX in a portfolio?

PortView shows DFTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.